We're on a mission to apply deep learning methods to drug discovery and use AI to accelerate and improve the drug discovery process. Our multi-disciplinary leadership team is focused on building Isomorphic Labs to help realize a new age of biomedical breakthroughs and ultimately to find cures for many of our most devastating diseases.
Demis Hassabis, PhD
Demis Hassabis is the Founder and CEO of Isomorphic Labs. He is also the co-founder and CEO of DeepMind, the world’s leading AI research company that has produced landmark research breakthroughs such as AlphaGo, the first program to beat the world champion at the game of Go, and AlphaFold, which was heralded as a solution to the 50-year grand challenge of protein folding. A chess and programming prodigy, Demis is a renowned computer scientist, neuroscientist and videogame designer. Demis designed and programmed the award-winning game Theme Park at the age of 17 and went on to graduate from Cambridge University and complete a PhD in cognitive neuroscience at University College London. His research has been featured by the journal Science in their Top 10 Breakthroughs of the Year on four separate occasions. Demis is a Fellow of the Royal Society and the Royal Academy of Engineering, in 2017 he featured in the Time 100 list of most influential people, and in 2018 he was awarded a CBE for services to science and technology.
Sergei Yakneen, PhD
Dr. Yakneen is the Chief Technology Officer, and brings over 20 years experience in engineering, machine learning, product, life science, and medical research to his role at Isomorphic Labs. Prior to this role he was senior vice president and chief technology officer at SOPHiA GENETICS, where he was responsible for the development and operation of a global AI-based molecular diagnostics and imaging software platform operating in more than 70 countries. He’s held senior roles at Amazon.com, where he launched the first Canadian software engineering center; at BPS Inc., where he developed a best-in-class Governance, Risk, and Compliance platform; at the Ontario Institute for Cancer Research, where he led the Technical Working Group of the Pan Cancer Analysis of Whole Genomes Project, the world’s largest cancer data analysis initiative; and at EMBL where he developed a cloud-based scientific workflow framework. Dr. Yakneen holds a degree in computer science and mathematics from the University of Toronto and a PhD in computer science from Heidelberg University, where he developed novel distributed algorithms for analyzing cancer genomes.
Miles Congreve, PhD
Dr. Congreve is the Chief Scientific Officer at Isomorphic Labs. He joined the company from Sosei Heptares in the same role, where he pioneered Structure-Based Drug Design for G Protein-Coupled Receptors (GPCRs). Previously he was director of chemistry at Astex Pharmaceuticals, helping to establish Fragment-Based Drug Design as a radical new approach to small molecule lead generation, and team leader at GlaxoSmithKline in medicinal chemistry and chemical technologies. In his 28-year career, Dr. Congreve has contributed to the design of 20 clinically evaluated drugs and he is co-inventor of Kisqali® (Ribociclib), a marketed treatment for breast cancers. He is co-author of over 180 publications and patents. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares. Dr. Congreve has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University. He is also a fellow of the Royal Society of Chemistry.
Max Jaderberg, PhD
Dr. Jaderberg is the Director of Machine Learning at Isomorphic Labs. He joined the company from DeepMind, where he was a research scientist leading the Open-Ended Learning research team and pioneering numerous algorithms bringing together large-scale deep learning and reinforcement learning to achieve breakthrough results with AI. Prior to that, he was CEO and co-founder of Vision Factory, a company that specialized in image recognition technology with deep learning, which was acquired by Google in 2014 and subsequently became part of DeepMind. He is widely published in the top journals and conferences, with work now part of textbooks. His research interests are in AI, deep learning, reinforcement learning and generative modeling. Dr. Jaderberg completed his undergraduate degree in engineering science at the University of Oxford and his PhD with the Visual Geometry Group at the University of Oxford, where he developed state-of-the-art algorithms for image understanding.
Ms. Richenburg is the Director of People Operations. She joined Isomorphic Labs from Eigen Technologies, where she was senior vice president of people. She is skilled in the development and implementation of innovative people strategies that drive business growth and performance. She has held a variety of human resources roles at companies including Meridian Life Sciences, Bioline and Evotec. Ms. Richenburg is a graduate of the University of Edinburgh with a bachelor’s degree in chemistry, medicinal and biological chemistry and earned a master’s degree in human resources management from Oxford Brookes University.
The company is continuing to scale and is currently seeking talent at various levels with a focus on scientific, engineering and operational roles, along with biologists, medicinal chemists, biophysicists, clinicians, computational scientists, and machine learning experts to contribute to our mission of using AI to accelerate the drug discovery process. For information on open roles, please visit www.isomorphiclabs.com/join.